Idrotens

Hydrochlorothiazide and Candesartan Cilexetil, the active ingredient in Idrotens, is an angiotensin II receptor blocker and thiazide diuretic presented as an oral tablet for hypertension management in adults. It combines vasodilation with diuresis to achieve effective blood‑pressure control.

GNH USA supplies Idrotens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idrotens is an oral antihypertensive that targets the renin‑angiotensin system and renal sodium reabsorption to lower blood pressure.

- Essential hypertension: reduces systolic and diastolic pressure and lowers cardiovascular risk. - Secondary hypertension: assists in blood‑pressure control when underlying causes are present. - Hypertension with fluid retention: provides both vasodilation and diuretic action to manage excess fluid.

Common Side Effects: - Dizziness or light‑headedness. - Increased urination. - Headache. - Fatigue. - Electrolyte disturbances such as low potassium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling). - Significant electrolyte imbalance (hyperkalemia, hyponatremia). - Acute kidney injury or worsening renal function. - Angioedema affecting face, lips, or airway. - Pancreatitis. - Liver enzyme elevation.

Before initiating therapy, clinicians should assess renal function, electrolyte status, and potential drug interactions.

- Monitor electrolytes: check potassium and sodium levels regularly. - Assess renal function: evaluate creatinine and eGFR before and during treatment. - Use caution in elderly patients: increased sensitivity to blood‑pressure changes. - Avoid concurrent use with other potassium‑sparing agents without monitoring. - Review hepatic impairment: adjust if severe liver disease is present. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Idrotens may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can increase risk of renal impairment. - Potassium supplements or high‑potassium diet: may cause hyperkalemia. - Lithium: increased lithium levels and toxicity risk. - NSAIDs: may reduce antihypertensive efficacy and affect renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect; monitor for hypotension. - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustment. - Diuretics (loop or potassium‑sparing): monitor electrolytes and renal function. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase candesartan plasma concentrations.